Skip to main content
Premium Trial:

Request an Annual Quote

Ezose, Hirosaki University Partner on Glycomics Research Targeting Prostate Cancer

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Ezose Sciences and Hirosaki University in Japan today announced a glycomics research collaboration to identify new biomarkers for the prediction and monitoring of progress of prostate cancer and other urological cancers.

Under the terms of the deal, Hirosaki researchers will collect urine samples from well-characterized patients and control populations in Japan, and Ezose will analyze the samples using its GlycanMap platform.

Hirosaki University is granting Pine Brook, NJ-based Ezose the exclusive rights to develop and commercialize new biomarkers resulting from the deal. Other terms were not disclosed.

"Given the already established clinical utility of glycan-based biomarkers in certain cancers, we believe that further studies in oncology hold promise for identifying other novel biomarkers that could help guide clinical practice," Hidehisa Asada, vice president of R&D at Ezose, said in a statement.

Ezose's GlycanMap uses an automated 96-well, bead-based glycan enrichment platform linked to MALDI-TOF mass spectrometry to identify and quantify glycans in biological samples like blood and tissue.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.